1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Global Biopharmaceutical Market Report & Forecast (2016-2021)

Global Biopharmaceutical Market Report & Forecast (2016-2021)

  • July 2016
  • -
  • International Market Analysis Research and Consult
  • -
  • 194 pages

The global biopharmaceutical Industry has come a long way since its first drug- Humulin was approved in 1982. Today hundreds of biopharmaceuticals have already been approved and many more are in late stages of clinical development. These drugs have not only advanced the prevention and treatment of a number of life threatening diseases but have also provided the thrust for the continued success of the pharmaceutical industry.

Under mounting economic pressures to increase their outputs, pharmaceutical manufacturers have embraced biopharmaceuticals as a means to maintain flow in their drying pipelines. Bringing a biopharmaceutical, however, represents a very risky proposition as out of every ten drugs that enter the clinical phases, only three manage to gain market approval. But the industry’s multibillion dollar revenues and strong growth rates in previous years bears a testimony to the fact that the ones that finally do get approval represent goldmines for investors.

Although factors like biosimilar entry and cost containment in the developed markets are likely to restrain the growth of this market in the coming years, IMARC expects that with their high potency and ability to attack targets beyond the reach of traditional small molecule drugs, biopharmaceuticals provide the industry with a huge scope for future growth. A rich late stage pipeline and increasing demand in emerging markets are also expected to be major drivers in the coming years.

The study covers the market analysis of various segments and sub-segments of the biopharmaceutical industry based on class and key indicative areas. Recombinant proteins currently represent the biggest segment on the basis of class accounting for the majority of the global biopharmaceutical sales. Recombinant proteins are followed by monoclonal antibodies and purified proteins. On the basis of key indicative and therapeutic application areas for biopharmaceuticals, autoimmune diseases represent the largest segment followed by oncology. With most of the current and future monoclonal antibodies targeted against autoimmune diseases such as rheumatoid arthritis and oncology, autoimmune diseases and oncology will continue to represent the dominant indications for biopharmaceuticals over the next five years.

The biopharmaceutical market is largely dominated by the US accounting for nearly half of the total global sales. The other top markets include Germany, Japan, France, Italy, Spain, UK and Canada. Moreover, increasing disposable incomes and a larger access to healthcare insurance, the market for biopharmaceuticals is also expected to expand and offer great opportunities and growth prospects across various emerging markets over the next few years. The report has also provided a robust analysis of the key players operating in the global biopharmaceutical market. Some of the key players analysed in this report include: Roche, Amgen, Novo Nordisk, AbbVie and Sanofi.

IMARC’s new report “Global Biopharmaceutical Market Report & Forecast (2016-2021)” gives a deep insight into the global biopharmaceutical market. The research study serves as an analytical as well as a statistical tool to understand the strengths, weaknesses, opportunities, threats, market trends, geographical structure, therapeutic structure, competitive structure and the outlook of the global biopharmaceutical market till 2021. This report will serve as an excellent guide for investors, researchers, consultants, marketing strategists, and all those who are planning to foray into the global biopharmaceutical market in any form.

What We Have Achieved in this Report?

Deep Qualitative Understanding of Various Factors Driving and Restraining the Global Biopharmaceutical Market

Key Aspects Analyzed:

Driving Factors
Restraining Factors
Market Opportunities
Threats
Comprehensive Situation Analysis of the Global Biopharmaceutical Market and its Dynamics

Regions/Countries Covered:

North America: United States and Canada

Latin America: Mexico, Brazil and Argentina

Europe: Germany, France, Italy, Spain, United Kingdom, Russia and Turkey

Asia Pacific: Japan, China, Australia, South Korea, India and Indonesia

Classes Covered for Each Country: Erythropoietins, Insulin, Interferons, Growth Hormones, Immunoglobulins, Colony Stimulating Factors, Recombinant Blood Factors, Recombinant Enzymes, Growth Factors, Interleukins, Monoclonal Antibodies and Purified Proteins

Focus of the Analysis for Each Country:

Total Market Performance
Performance of Various Classes
Performance of Top Players
Market Forecast
Key Questions Answered in this Report:

What are the key advantages/ disadvantages of biopharmaceuticals over small molecule drugs in terms of efficacy, safety, price, approval times, market growth, etc.?
What are the key opportunities and threats faced by the biopharmaceutical industry?
What has been the historical and current performance of the global biopharmaceutical market and how is it expected to perform in the coming years?
Which are the world’s largest biopharmaceutical markets?
Which are the world’s fastest growing biopharmaceutical markets?
What is the structure and composition of various biopharmaceutical markets across the globe?
Which are the world’s largest biopharmaceutical segments?
Which are the world’s fastest growing biopharmaceutical segments?
Who are the world’s largest biopharmaceutical companies and how have they performed in recent years?

Table Of Contents

Global Biopharmaceutical Market Report and Forecast (2016-2021)
1. Market Definitions and Research Methodology
2. Analyst Briefing
3. Introduction to Biopharmaceuticals
4. Global Biopharmaceutical Market: Industry Performance
4.1 Market Performance and Forecast
4.1.1 Current Performance (2008-2015)
4.1.2 Market Forecast (2016-2021)
4.2 Market Segmentation by Region
4.2.1 Current Performance (2008-2015)
4.2.2 Market Forecast (2016-2021)
4.3 Market Segmentation by Indication
4.3.1 Autoimmune Diseases
4.3.2 Oncology
4.3.3 Metabolic Disorders
4.3.4 Others
4.4 Market Segmentation by Class
4.4.1 Recombinant Proteins
4.4.1.1 Current Performance (2008-2015)
4.4.1.2 Market Forecast (2016-2021)
4.4.2 Monoclonal Antibodies
4.4.2.1 Current Performance (2008-2015)
4.4.2.2 Market Forecast (2016-2021)
4.4.3 Purified Proteins
4.4.3.1 Current Performance (2008-2015)
4.4.3.2 Market Forecast (2016-2021)
4.5 Competitive Landscape
4.5.1 Top Biopharmaceutical Players
4.5.1.1 Roche
4.5.1.2 Amgen
4.5.1.3 Novo Nordisk
4.5.1.4 AbbVie
4.5.1.5 Sanofi
4.5.2 Top Biopharmaceutical Drugs
4.5.2.1 Humira
4.5.2.2 Remicade
4.5.2.3 Rituxan
4.5.2.4 Enbrel
4.5.2.5 Lantus
5. North America
5.1 US
5.1.1 Market Performance (2008-2015)
5.1.2 Market Segmentation by Class
5.1.2.1 Recombinant Proteins
5.1.2.2 Monoclonal Antibodies
5.1.2.3 Purified Proteins
5.1.3 Performance of Top Players
5.1.4 Market Forecast (2016-2021)
5.2 Canada
5.2.1 Market Performance (2008-2015)
5.2.2 Market Segmentation by Class
5.2.2.1 Recombinant Proteins
5.2.2.2 Monoclonal Antibodies
5.2.3 Performance of Top Players
5.2.4 Market Forecast (2016-2021)
6. Latin America
6.1 Mexico
6.1.1 Market Performance (2008-2015)
6.1.2 Market Segmentation by Class
6.1.2.1 Recombinant Proteins
6.1.2.2 Monoclonal Antibodies
6.1.2.3 Purified Proteins
6.1.3 Performance of Top Players
6.1.4 Market Forecast (2016-2021)
6.2 Brazil
6.2.1 Market Performance (2008-2015)
6.2.2 Market Segmentation by Class
6.2.2.1 Recombinant Proteins
6.2.2.2 Monoclonal Antibodies
6.2.2.3 Purified Proteins
6.2.3 Performance of Top Players
6.2.4 Market Forecast (2016-2021)
6.3 Argentina
6.3.1 Market Performance (2008-2015)
6.3.2 Market Segmentation by Class
6.3.2.1 Recombinant Proteins
6.3.2.2 Monoclonal Antibodies
6.3.2.3 Purified Proteins
6.3.3 Performance of Top Players
6.3.4 Market Forecast (2016-2021)
7. Europe
7.1 Germany
7.1.1 Market Performance (2008-2015)
7.1.2 Market Segmentation by Class
7.1.2.1 Recombinant Proteins
7.1.2.2 Monoclonal Antibodies
7.1.2.3 Purified Proteins
7.1.3 Performance of Top Players
7.1.4 Market Forecast (2016-2021)
7.2 France
7.2.1 Market Performance (2008-2015)
7.2.2 Market Segmentation by Class
7.2.2.1 Recombinant Proteins
7.2.2.2 Monoclonal Antibodies
7.2.2.3 Purified Proteins
7.2.3 Performance of Top Players
7.2.4 Market Forecast (2016-2021)
7.3 Italy
7.3.1 Market Performance (2008-2015)
7.3.2 Market Segmentation by Class
7.3.2.1 Recombinant Proteins
7.3.2.2 Monoclonal Antibodies
7.3.2.3 Purified Proteins
7.3.3 Performance of Top Players
7.3.4 Market Forecast (2016-2021)
7.4 Spain
7.4.1 Market Performance (2008-2015)
7.4.2 Market Segmentation by Class
7.4.2.1 Recombinant Proteins
7.4.2.2 Monoclonal Antibodies
8.4.2.3 Purified Proteins
7.4.3 Performance of Top Players
7.4.4 Market Forecast (2016-2021)
7.5 UK
7.5.1 Market Performance (2008-2015)
7.5.2 Market Segmentation by Class
7.5.2.1 Recombinant Proteins
7.5.2.2 Monoclonal Antibodies
7.5.2.3 Purified Proteins
7.5.3 Performance of Top Players
7.5.4 Market Forecast (2016-2021)
7.6 Russia
7.6.1 Market Performance (2008-2015)
7.6.2 Market Segmentation by Class
7.6.2.1 Recombinant Proteins
7.6.2.2 Monoclonal Antibodies
7.6.2.3 Purified Proteins
7.6.3 Performance of Top Players
7.6.4 Market Forecast(2016-2021)
7.7 Turkey
7.7.1 Market Performance (2008-2015)
7.7.2 Market Segmentation by Class
7.7.2.1 Recombinant Proteins
7.7.2.2 Monoclonal Antibodies
7.7.2.3 Purified Proteins
7.7.3 Performance of Top Players
7.7.4 Market Forecast (2016-2021)
8. Asia Pacific
8.1 Japan
8.1.1 Market Performance (2008-2015)
8.1.2 Market Segmentation by Class
8.1.2.1 Recombinant Proteins
8.1.2.2 Monoclonal Antibodies
8.1.2.3 Purified Proteins
8.1.3 Performance of Top Players
8.1.4 Market Forecast (2016-2021)
8.2 China
8.2.1 Market Performance (2008-2015)
8.2.2 Market Segmentation by Class
8.2.2.1 Recombinant Proteins
8.2.2.2 Monoclonal Antibodies
8.2.2.3 Purified Proteins
8.2.3 Performance of Top Players
8.2.4 Market Forecast (2016-2021)
8.3 Australia
8.3.1 Market Performance (2008-2015)
8.3.2 Market Segmentation by Class
8.3.2.1 Recombinant Proteins
8.3.2.2 Monoclonal Antibodies
8.3.2.3 Purified Proteins
8.3.3 Performance of Top Players
8.3.4 Market Forecast (2016-2021)
8.4 South Korea
8.4.1 Market Performance (2008-2015)
8.4.2 Market Segmentation by Class
8.4.2.1 Recombinant Proteins
8.4.2.2 Monoclonal Antibodies
8.4.2.3 Purified Proteins
8.4.3 Performance of Top Players
8.4.4 Market Forecast (2016-2021)
8.6 India
8.6.1 Market Performance (2008-2015)
8.6.2 Market Segmentation by Class
8.6.2.1 Recombinant Proteins
8.6.2.2 Monoclonal Antibodies
8.6.2.3 Purified Proteins
8.6.3 Performance of Top Players
8.6.4 Market Forecast (2016-2021)
8.6.5 Market Performance (2008-2015)
8.6.6 Market Segmentation by Class
8.6.6.1 Recombinant Proteins
8.6.6.2 Monoclonal Antibodies
8.6.7 Performance of Top Players
8.6.8 Market Forecast (2016-2021)
9. Global Biopharmaceutical Market: Industry Analysis
9.1 Strengths
9.1.1 High Efficacy and Target Oriented Attack
9.1.2 Strong Potential to Achieve Blockbuster Status
9.1.3 Limited Generic Threat
9.1.4 High Approval Success Rates
9.2 Weaknesses
9.2.1 Inconvenient Drug Delivery
9.2.2 Short Half Lives
9.2.3 Second Line of Therapy
9.2.4 High Cost of Therapy
9.2.5 Incidence of Unfavorable Side Effects
9.3 Opportunities
9.3.1 Diseases with High Unmet Needs
9.3.2 Approval into Additional Indications
9.3.3 Emerging Markets
9.3.4 New Approvals and a Strong Pipeline
9.4 Threats
9.4.1 Biopharmaceutical Drug Development is a Very Risky Venture
9.4.2 Biosimilars
9.4.3 Limited and Conditional Reimbursement
9.4.4 Uncertainties in the Economic Environment

List of Figures

Figure 2 1: Global Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
Figure 3 1: Complexity of Biopharmaceuticals
Figure 3 2: Sources of Biopharmaceuticals
Figure 5 1: Global: Biopharmaceutical Market (in Million US$), 2008-2015
Figure 5 2: Global: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
Figure 5 3: Global: Biopharmaceutical Market: Sales Share by Country (in %), 2015
Figure 5 4: Global: Biopharmaceutical Market Forecast: Sales Share by Country (in %), 2021
Figure 5 5: Global: Biopharmaceutical Market: Sales Share by Indication (in %), 2015
Figure 5 6: Global: Biopharmaceutical Market: Sales by Class (in Million US$), 2008-2015
Figure 5 8: Global: Biopharmaceutical Market Forecast: Sales by Class (in Million US$), 2016-2021
Figure 5 10: Global: Recombinant Proteins Market (in Million US$), 2008-2015
Figure 5 11: Global: Recombinant Proteins Market: Sales Share by Class (in %), 2015
Figure 5 12: Global: Recombinant Proteins Market Forecast (in Million US$), 2016-2021
Figure 5 14: Global: Monoclonal Antibodies Market (in Million US$), 2008-2015
Figure 5 15: Global: Monoclonal Antibodies Market: Sales Share by Class (in %), 2015
Figure 5 16: Global: Monoclonal Antibodies Market Forecast (in Million US$), 2016-2021
Figure 5 18: Global: Purified Proteins Market (in Million US$), 2008-2015
Figure 5 19: Global: Purified Proteins Market: Sales Share by Class (in %), 2015
Figure 5 20: Global: Purified Proteins Market Forecast (in Million US$), 2016-2021
Figure 5 22: Global Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
Figure 6 1: US: Biopharmaceutical Market (in Million US$), 2008-2015
Figure 6 2: US: Biopharmaceutical Market: Sales by Class (in Million US$), 2008-2015
Figure 6 4: US: Recombinant Proteins Market (in Million US$), 2008-2015
Figure 6 5: US: Recombinant Proteins Market: Sales Share by Class (in %), 2015
Figure 6 6: US: Monoclonal Antibodies Market (in Million US$), 2008-2015
Figure 6 7: US: Monoclonal Antibodies Market: Sales Share by Class (in %), 2015
Figure 6 8: US: Purified Proteins Market (in Million US$), 2008-2015
Figure 6 9: US: Purified Proteins Market: Sales Share by Class (in %), 2015
Figure 6 10: US: Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
Figure 6 11: US: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
Figure 6 13: Canada: Biopharmaceutical Market (in Million US$), 2008-2015
Figure 6 14: Canada: Biopharmaceutical Market: Sales by Class (in Million US$), 2008-2015
Figure 6 16: Canada: Recombinant Proteins Market (in Million US$), 2008-2015
Figure 6 17: Canada: Recombinant Proteins Market: Sales Share by Class (in %), 2015
Figure 6 18: Canada: Monoclonal Antibodies Market (in Million US$), 2008-2015
Figure 6 19: Canada: Monoclonal Antibodies Market: Sales Share by Class (in %), 2015
Figure 6 20: Canada: Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
Figure 6 21: Canada: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
Figure 6 22: Canada: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
Figure 7 1: Mexico: Biopharmaceutical Market (in Million US$), 2008-2015
Figure 7 2: Mexico: Biopharmaceutical Market: Sales by Class (in Million US$), 2008-2015
Figure 7 4: Mexico: Recombinant Proteins Market (in Million US$), 2008-2015
Figure 7 5: Mexico: Recombinant Proteins Market: Sales Share by Class (in %), 2015
Figure 7 6: Mexico: Monoclonal Antibodies Market (in Million US$), 2008-2015
Figure 7 7: Mexico: Monoclonal Antibodies Market: Sales Share by Class (in %), 2015
Figure 7 8: Mexico: Purified Proteins Market (in Million US$), 2008-2015
Figure 7 9: Mexico: Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
Figure 7 10: Mexico: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
Figure 7 11: Mexico: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
Figure 7 12: Brazil: Biopharmaceutical Market (in Million US$), 2008-2015
Figure 7 13: Brazil: Biopharmaceutical Market: Sales by Class (in Million US$), 2008-2015
Figure 7 15: Brazil: Recombinant Proteins Market (in Million US$), 2008-2015
Figure 7 16: Brazil: Recombinant Proteins Market: Sales Share by Class (in %), 2015
Figure 7 17: Brazil: Monoclonal Antibodies Market (in Million US$), 2008-2015
Figure 7 18: Brazil: Monoclonal Antibodies Market: Sales Share by Class (in %), 2015
Figure 7 19: Brazil: Purified Proteins Market (in Million US$), 2008-2015
Figure 7 20: Brazil: Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
Figure 7 21: Brazil: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
Figure 7 22: Brazil: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
Figure 7 23: Argentina: Biopharmaceutical Market (in Million US$), 2008-2015
Figure 7 24: Argentina: Biopharmaceutical Market: Sales by Class (in Million US$), 2008-2015
Figure 7 26: Argentina: Recombinant Proteins Market (in Million US$), 2008-2015
Figure 7 27: Argentina: Recombinant Proteins Market: Sales Share by Class (in %), 2015
Figure 7 28: Argentina: Monoclonal Antibodies Market (in Million US$), 2008-2015
Figure 7 29: Argentina: Monoclonal Antibodies Market: Sales Share by Class (in %), 2015
Figure 7 30: Argentina: Purified Proteins Market (in Million US$), 2008-2015
Figure 7 31: Argentina: Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
Figure 7 32: Argentina: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
Figure 7 33: Argentina: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
Figure 8 1: Germany: Biopharmaceutical Market (in Million US$), 2008-2015
Figure 8 2: Germany: Biopharmaceutical Market: Sales by Class (in Million US$), 2008-2015
Figure 8 4: Germany: Recombinant Proteins Market (in Million US$), 2008-2015
Figure 8 5: Germany: Recombinant Proteins Market: Sales Share by Class (in %), 2015
Figure 8 6: Germany: Monoclonal Antibodies Market (in Million US$), 2008-2015
Figure 8 7: Germany: Monoclonal Antibodies Market: Sales Share by Class (in %), 2015
Figure 8 8: Germany: Purified Proteins Market (in Million US$), 2008-2015
Figure 8 9: Germany: Purified Proteins Market: Sales Share by Class (in %), 2015
Figure 8 10: Germany: Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
Figure 8 11: Germany: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
Figure 8 12: Germany: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
Figure 8 13: France: Biopharmaceutical Market (in Million US$), 2008-2015
Figure 8 14: France: Biopharmaceutical Market: Sales by Class (in Million US$), 2008-2015
Figure 8 16: France: Recombinant Proteins Market (in Million US$), 2008-2015
Figure 8 17: France: Recombinant Proteins Market: Sales Share by Class (in %), 2015
Figure 8 18: France: Monoclonal Antibodies Market (in Million US$), 2008-2015
Figure 8 19: France: Monoclonal Antibodies Market: Sales Share by Class (in %), 2015
Figure 8 20: France: Purified Proteins Market (in Million US$), 2008-2015
Figure 8 21: France: Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
Figure 8 22: France: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
Figure 8 23: France: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
Figure 8 24: Italy: Biopharmaceutical Market (in Million US$), 2008-2015
Figure 8 25: Italy: Biopharmaceutical Market: Sales by Class (in Million US$), 2008-2015
Figure 8 27: Italy: Recombinant Proteins Market (in Million US$), 2008-2015
Figure 8 28: Italy: Recombinant Proteins Market: Sales Share by Class (in %), 2015
Figure 8 29: Italy: Monoclonal Antibodies Market (in Million US$), 2008-2015
Figure 8 30: Italy: Monoclonal Antibodies Market: Sales Share by Class (in %), 2015
Figure 8 31: Italy: Purified Proteins Market (in Million US$), 2008-2015
Figure 8 32: Italy: Biopharmaceutical Market: Sales Share of top players (in %), 2015
Figure 8 33: Italy: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
Figure 8 34: Italy: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
Figure 8 35: Spain: Biopharmaceutical Market (in Million US$), 2008-2015
Figure 8 36: Spain: Biopharmaceutical Market: Sales by Class (in Million US$), 2008-2015
Figure 8 38: Spain: Recombinant Proteins Market (in Million US$), 2008-2015
Figure 8 39: Spain: Recombinant Proteins Market: Sales Share by Class (in %), 2015
Figure 8 40: Spain: Monoclonal Antibodies Market (in Million US$), 2008-2015
Figure 8 41: Spain: Monoclonal Antibodies Market: Sales Share by Class (in %), 2015
Figure 8 42: Spain: Purified Proteins Market (in Million US$), 2008-2015
Figure 8 43: Spain: Purified Proteins Market: Sales Share by Class (in %), 2015
Figure 8 44: Spain: Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
Figure 8 45: Spain: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
Figure 8 46: Spain: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
Figure 8 47: UK: Biopharmaceutical Market (in Million US$), 2008-2015
Figure 8 48: UK: Biopharmaceutical Market, Sales by Class (in Million US$), 2008-2015
Figure 8 50: UK: Recombinant Proteins Market (in Million US$), 2008-2015
Figure 8 51: UK: Recombinant Proteins Market: Sales Share by Class (in %), 2015
Figure 8 52: UK: Monoclonal Antibodies Market (in Million US$), 2008-2015
Figure 8 53: UK: Monoclonal Antibodies Market: Sales Share by Class (in %), 2015
Figure 8 54: UK: Purified Proteins Market (in Million US$), 2008-2015
Figure 8 55: UK: Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
Figure 8 56: UK: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
Figure 8 57: UK: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
Figure 8 58: Russia: Biopharmaceutical Market (in Million US$), 2008-2015
Figure 8 59: Russia: Biopharmaceutical Market: Sales by Class (in Million US$), 2008-2015
Figure 8 61: Russia: Recombinant Proteins Market (in Million US$), 2008-2015
Figure 8 62: Russia: Recombinant Proteins Market: Sales Share by Class (in %), 2015
Figure 8 63: Russia: Monoclonal Antibodies Market (in Million US$), 2008-2015
Figure 8 64: Russia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2015
Figure 8 65: Russia: Purified Proteins Market (in Million US$), 2008-2015
Figure 8 66: Russia: Purified Proteins Market: Sales Share by Class (in %), 2015
Figure 8 67: Russia: Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
Figure 8 68: Russia: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
Figure 8 69: Russia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
Figure 8 70: Turkey: Biopharmaceutical Market (in Million US$), 2008-2015
Figure 8 71: Turkey: Biopharmaceutical Market: Sales by Class (in Million US$), 2008-2015
Figure 8 73: Turkey: Recombinant Proteins Market (in Million US$), 2008-2015
Figure 8 74: Turkey: Recombinant Proteins Market: Sales Share by Class (in %), 2015
Figure 8 75: Turkey: Monoclonal Antibodies Market: Sales Share by Class (in %), 2015
Figure 8 76: Turkey: Purified Proteins Market (in Million US$), 2008-2015
Figure 8 77: Turkey: Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
Figure 8 78: Turkey: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
Figure 8 79: Turkey: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
Figure 9 1: Japan: Biopharmaceutical Market (in Million US$), 2008-2015
Figure 9 2: Japan: Biopharmaceutical Market: Sales by Class (in Million US$), 2008-2015
Figure 9 4: Japan: Recombinant Proteins Market (in Million US$), 2008-2015
Figure 9 5: Japan: Recombinant Proteins Market: Sales Share by Class (in %), 2015
Figure 9 6: Japan: Monoclonal Antibodies Market (in Million US$), 2008-2015
Figure 9 7: Japan: Monoclonal Antibodies Market: Sales Share by Class (in %), 2015
Figure 9 8: Japan: Purified Proteins Market (in Million US$), 2008-2015
Figure 9 9: Japan: Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
Figure 9 10: Japan: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
Figure 9 11: Japan: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
Figure 9 12: China: Biopharmaceutical Market (in Million US$), 2008-2015
Figure 9 13: China: Biopharmaceutical Market: Sales by Class (in Million US$), 2008-2015
Figure 9 15: China: Recombinant Proteins Market (in Million US$), 2008-2015
Figure 9 16: China: Recombinant Proteins Market: Sales Share by Class (in %), 2015
Figure 9 17: China: Monoclonal Antibodies Market (in Million US$), 2008-2015
Figure 9 18: China: Monoclonal Antibodies Market: Sales Share by Class (in %), 2015
Figure 9 19: China: Purified Proteins Market (in Million US$), 2008-2015
Figure 9 20: China: Purified Proteins Market: Sales Share by Class (in %), 2015
Figure 9 21: China: Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
Figure 9 22: China: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
Figure 9 23: China: BiopharmaceuticalMarket Forecast: Sales Share by Class (in %), 2021
Figure 9 24: Australia: Biopharmaceutical Market (in Million US$), 2008-2015
Figure 9 25: Australia: Biopharmaceutical Market: Sales by Class (in Million US$), 2008-2015
Figure 9 27: Australia: Recombinant Proteins Market (in Million US$), 2008-2015
Figure 9 28: Australia: Recombinant Proteins Market: Sales Share by Class (in %), 2015
Figure 9 29: Australia: Monoclonal Antibodies Market (in Million US$), 2008-2015
Figure 9 30: Australia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2015
Figure 9 31: Australia: Purified Proteins Market (in Million US$), 2008-2015
Figure 9 32: Australia: Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
Figure 9 33: Australia: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
Figure 9 34: Australia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
Figure 9 35: South Korea: Biopharmaceutical Market (in Million US$), 2008-2015
Figure 9 36: South Korea: Biopharmaceutical Market: Sales by Class (in Million US$), 2008-2015
Figure 9 38: South Korea: Recombinant Proteins Market (in Million US$), 2008-2015
Figure 9 39: South Korea: Recombinant Proteins Market: Sales Share by Class (in %), 2015
Figure 9 40: South Korea: Monoclonal Antibodies Market (in Million US$), 2006 - 2012
Figure 9 41: South Korea: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2015
Figure 9 42: South Korea: Purified Proteins Market (in Million US$), 2008-2015
Figure 9 43: South Korea: Purified Proteins Market: Sales Share by Class (in %), 2015
Figure 9 44: South Korea: Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
Figure 9 45: South Korea: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
Figure 9 46: South Korea: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
Figure 9 47: India: Biopharmaceutical Market (in Million US$), 2008-2015
Figure 9 48: India: Biopharmaceutical Market: Sales by Class (in Million US$), 2008-2015
Figure 9 50: India: Recombinant Proteins Market (in Million US$), 2008-2015
Figure 9 51: India: Recombinant Proteins Market: Sales Share by Class (in %), 2015
Figure 9 52: India: Monoclonal Antibodies Market (in Million US$), 2008-2015
Figure 9 53: India: Purified Proteins Market (in Million US$), 2008-2015
Figure 9 54: India: Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
Figure 9 55: India: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
Figure 9 56: India: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
Figure 9 57: Indonesia: Biopharmaceutical Market (in Million US$), 2008-2015
Figure 9 58: Indonesia: Biopharmaceutical Market: Sales by Class (in Million US$), 2008-2015
Figure 9 60: Indonesia: Recombinant Proteins Market (in Million US$), 2008-2015
Figure 9 61: Indonesia: Recombinant Proteins Market: Sales Share by Class (in %), 2015
Figure 9 62: Indonesia: Monoclonal Antibodies Market (in Million US$), 2008-2015
Figure 9 63: Indonesia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2015
Figure 9 64: Indonesia: Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
Figure 9 65: Indonesia: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
Figure 9 66: Indonesia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
Figure 4 1: Global: Share of Biopharmaceuticals and Small Molecule Drugs Among the Top Ten Selling Drugs (in %), 2000and 2012
Figure 4 2: Using a Different Manufacturing Process Makes it Extremely Difficult for Biosimilars to be Equivalent to Originator Products
Figure 4 3: Marked Differences Between Biosimilar and Branded Biopharmaceuticals When a Different Production Process was Used
Figure 4 4: Transition Probabilities of Biopharmaceuticals and Small Molecule Drugs in Clinical Phases, (in %)
Figure 4 5: Comparison of the Average Annual Cost of Therapy Using Biopharmaceuticals and Small Molecule Drugs (in US$)
Figure 4 6: Comparison of the Annual Cost of Therapy for Plaque Psoriasis Using Biopharmaceuticals and Small Molecule Drugs (in US$)
Figure 4 7: Emerging Biopharmaceutical Market Forecast (in Million US$), 2016and 2021
Figure 4 8: Developed Biopharmaceutical Market Forecast (in Million US$), 2016and 2021
Figure 4 9: Breakup of Biopharmaceuticals and Small Molecule Drugs Receiving FDA Approval (in Numbers), 1997- 2011
Figure 4 10: Breakup of Biopharmaceuticals and Small Molecule Drugs Receiving FDA Approval (in %), 1997 - 2011
Figure 4 11: Global: Breakup of Small Molecule Drugs and Biopharmaceuticals in the Total Pharmaceutical Market and Phase III development (%), 2011
Figure 4 12: A Comparison of the Costs Incurred While Developing Biopharmaceuticals and Small Molecule Drugs (in Million US$)
Figure 4 13: Research and Development Times Taken by Biopharmaceuticals to Reach the Market (in Months), 1982-89,1990-94,1995-99, 2000-04, 2005-09
Figure 4 14: Comparison of the Research and Development Times for Biopharmaceuticals and Small Molecule Drugs (in Months)
Figure 4 15: US, Germany, France, Italy, Spain and UK: Somatropin Biosimilars: Patient Share (in %), 2007-2011
Figure 4 16: Germany, France, Italy, Spain and UK: Epoetin AlfaBiosimilars: Patient Share (in %), 2007-2011
Figure 4 17: Germany, France, Italy, Spain and UK: FilgrastimBiosimilars: Patient Share (in %), 2008-2011
Figure 4 18: Current Medicare Payer Coverage for Monoclonal Antibodies
Figure 4 19: Performance of Biotech Stocks During the Financial Crisis (in %), Jan 2008 to Dec 2008

List of Tables

Table 1 1: Global: Biopharmaceutical Market: Definition and Segmentation
Table 2 1: Global: Biopharmaceutical Market: SWOT Analysis
Table 2 2: Global: Recombinant Proteins Market Forecast: Sales by Class (in Million US$),
Table 2 3: Global: Monoclonal Antibodies Market Forecast: Sales by Class (In Million US$), 2016and 2021
Table 2 4: Global: Purified Proteins Market Forecast: Sales by Class (In Million US$), 2016and 2021
Table 2 5: Global: Biopharmaceutical Market Forecast: Sales by Region (In Million US$), 2016and 2021
Table 3 1: Differences Between Small Molecule Drugs and Biopharmaceuticals
Table 3 2: Complexity of Manufacturing Process Involved with Biopharmaceuticals and Small Molecule Drugs
Table 5 1: Global: Biopharmaceutical Market: Sales by Country (in Million US$), 2008-2015
Table 5 2: Global: Biopharmaceutical Market Forecast: Sales by Country (in Million US$), 2016-2021
Table 5 3: Global: Biopharmaceutical Market: Sales by Indication (in Billion US$), 2015
Table 5 4: Global: Contribution of Various Classes to Total Biopharmaceutical Growth (in Million US$), 2016-2021
Table 5 13: Global: Purified Proteins Market: Sales by Class (in Million US$), 2008-2015
Table 5 19: Global: Biopharmaceutical Market Forecast: Sales of Top Biopharmaceuticals (in Million US$), 2015 and 2021
Table 7 12: Brazil: Purified Proteins Market: Sales by Class (in Million US$), 2008-2015
Table 7 14: Brazil: Biopharmaceutical Market: Sales of Top Players (in Million US$), 2008-2015
Table 4 1: Global: Top Ten Selling Drugs (Based on Origin), 2000
Table 4 2: Global: Top Ten Selling Drugs (Based on Origin), 2012
Table 4 4: Mode of Administration of Popular Biotech Drugs
Table 4 5: FDA: Total Number of Biopharmaceutical Approvals in 2011
Table 4 6: US and European Statistics of Branded Biopharmaceutical Products Facing Biosimilar Threat (in Million US$), 2011

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Single-use Bioreactor Market by Product, Cell, Technology, Application, End User - Global Forecast to 2021

Single-use Bioreactor Market by Product, Cell, Technology, Application, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global single-use bioreactors market is projected to reach USD 1,085.7 million by 2021 from USD 408.4 million in 2016, growing at a CAGR of 21.6% during the forecast period (2016–2021). In this report, ...

Global Biopharmaceuticals Market Growth, Trends & Forecasts (2016 - 2021)

Global Biopharmaceuticals Market Growth, Trends & Forecasts (2016 - 2021)

  • $ 4250
  • Industry report
  • September 2016
  • by Mordor Intelligence LLP

In the year 2015, the global market for biopharmaceuticals was valued at USD 176.9 billion. It is estimated at USD 192.2 million for the year 2016 and is projected to reach USD 291 billion by the yea ...

Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010 to 2016

Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010 to 2016

  • $ 2995
  • Industry report
  • September 2016
  • by Currentpartnering

The Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2016 report provides comprehensive understanding and unprecedented access to the co-development deals and ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.